Immunity to HIV in Early Life

Area of Science:

• Pediatric Immunology
• Infectious Diseases
• HIV Pathogenesis

Background:

• The developing immune system in children is uniquely susceptible to infections like HIV due to its tolerogenic state and lack of immunological memory.
• HIV pathogenesis in children differs from adults, characterized by faster progression and poorer viral load control, leading to higher susceptibility.
• Infants exhibit high plasma viral loads that gradually decrease with immune maturation, even in some cases without antiretroviral therapy (ART).

Purpose of the Study:

• To review the complex interactions between Human Immunodeficiency Virus (HIV) and the developing immune system in pediatric populations.
• To explore the implications of these interactions for novel therapeutic and prophylactic interventions against HIV in children.
• To discuss the potential for early antiretroviral therapy (ART) to prevent viral reservoirs and achieve functional cure in newborns.

Main Methods:

• Review of existing literature on pediatric HIV infection and immune development.
• Analysis of clinical observations and case reports, including the "Mississippi child" case.
• Discussion of immunological factors influencing HIV disease progression in children.

Main Results:

• Children's immature immune systems are less equipped to control HIV, leading to rapid disease progression and high viral loads.
• Low frequencies of central memory CD4+ T-lymphocytes in newborns present a potential window for early intervention to prevent viral reservoirs.
• Sustained viral suppression post-ART cessation may require additional immunomodulatory strategies beyond immediate ART.

Conclusions:

• The unique immunological environment in children offers potential opportunities for innovative HIV interventions, including early ART.
• Achieving a functional cure for pediatric HIV may necessitate a combination of ART and immunomodulatory approaches.
• Further research is crucial to develop effective strategies for preventing and treating HIV in the pediatric population.